We require at least 2mL of whole blood sample in an EDTA-treated tube.
PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.
We do not recommend using ImpriMed's predictions to rule out treatment options. The company's artificial intelligence is optimized to give high positive predictive value to help you find drugs with the highest likelihood of producing positive clinical outcomes. For the bests results, our predictions should be used in conjunction with expert knowledge from a skilled oncologist.
Our flow cytometry, PARR, and Immunoprofile reports are emailed to you 3-4 days after receipt of your patient’s sample(s) at our lab. The Personalized Prediction Profile reports are emailed to you 6-7 days after receipt of your patient’s sample(s) at our lab.
Disinfect the skin with alcohol (70%) at the planned needle puncture site. Insert a 20-gauge needle (without syringe) into an enlarged lymph node and perform 15 - 20 aspirations using an aggressive “woodpecker style” technique. (Click to Read More)
Yes, you can select non-MDR1 drugs when indicating your drug priorities, but the final report will also include all drugs.
